Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Carl L. G. Hansen net worth and biography

Carl Hansen Biography and Net Worth

CEO of AbCellera Biologics

Carl Hansen is AbCellera’s founding CEO. Until August 2019, Carl was a Professor at the University of British Columbia, where he co-authored over 65 manuscripts in the fields of microfluidics, immunology, genomics, and nanotechnology. He is an inventor of over 50 US patents and 63 US patent applications that are represented in 7 commercial products. He received the Michael Smith Career investigator award and was recently named one of the “Top 5 Canadian CEOs who elevate their companies.” Carl received his PhD in Applied Physics/Biotechnology from Caltech, and a BASc in Engineering Physics and Honors Mathematics from the University of British Columbia. Before leading AbCellera, he was a scientific Co-Founder of Precision Nanosystems, a Vancouver-based company developing next-generation delivery technology for genetic medicines, and served on the SAB of Fluidigm Corp.

How old is Carl L. G. Hansen?: Dr. Hansen is currently 49 years old. There are 4 older executives and no younger executives at AbCellera Biologics. The oldest executive at AbCellera Biologics is Mr. Tryn T. Stimart Esq., J.D., M.Sc., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer, who is 54 years old. Learn More on Carl L. G. Hansen's age.
How do I contact Carl L. G. Hansen?: The corporate mailing address for Dr. Hansen and other AbCellera Biologics executives is , , . AbCellera Biologics can also be reached via phone at 604-559-9005 and via email at [email protected]. Learn More on Carl L. G. Hansen's contact information.
Has Carl L. G. Hansen been buying or selling shares of AbCellera Biologics?: Carl L. G. Hansen has not been actively trading shares of AbCellera Biologics during the last ninety days. Most recently, Carl L. G. Hansen sold 6,000,000 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $24.13, for a transaction totalling $144,780,000.00. Learn More on Carl L. G. Hansen's trading history.
Who are AbCellera Biologics' active insiders?: AbCellera Biologics' insider roster includes Andrew Booth (CFO), John Hamer (Director), Carl Hansen (CEO), Michael Hayden (Director), Veronique Lecault (COO), Andrew Lo (Director), and John Montalbano (Director). Learn More on AbCellera Biologics' active insiders.
Are insiders buying or selling shares of AbCellera Biologics?: During the last year, AbCellera Biologics insiders bought shares 2 times. They purchased a total of 167,500 shares worth more than $1,096,885.00. The most recent insider tranaction occured on May, 26th when CFO Andrew Booth bought 14,500 shares worth more than $99,325.00. Insiders at AbCellera Biologics own 32.5% of the company. Learn More about insider trades at AbCellera Biologics.
Information on this page was last updated on 5/26/2023.

Carl L. G. Hansen Insider Trading History at AbCellera Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/9/2021	Sell	6,000,000	$24.13	$144,780,000.00

Carl L. G. Hansen Buying and Selling Activity at AbCellera Biologics

AbCellera Biologics Company Overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Today's Range

Now: $4.18

$4.15

$4.34

50 Day Range

MA: $4.79

$4.18

$5.46

2 Week Range

Now: $4.18

$3.87

$8.05

Volume

1,358,936 shs

Average Volume

1,384,034 shs

Market Capitalization

$1.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Forget Nvidia, buy this A.I. Stock Now

From InvestorPlace | Ad

Click here to see the details.